News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
332,049 Results
Type
Article (14423)
Company Profile (21)
Press Release (317605)
Multimedia
Podcasts (59)
Webinars (8)
Section
Business (86029)
Career Advice (859)
Deals (20313)
Drug Delivery (51)
Drug Development (53452)
Employer Resources (54)
FDA (8888)
Job Trends (6653)
News (169686)
Policy (16231)
Tag
2027 Genetown Standard (1)
Academia (971)
Accelerated approval (23)
Adcomms (14)
Allergies (86)
Alliances (20509)
ALS (111)
Alzheimer's disease (1037)
Antibody-drug conjugate (ADC) (183)
Approvals (9195)
Artificial intelligence (233)
Autoimmune disease (85)
Automation (11)
Bankruptcy (218)
Best Places to Work (6120)
BIOSECURE Act (5)
Biosimilars (93)
Biotechnology (23)
Bladder cancer (127)
Brain cancer (37)
Breast cancer (417)
Cancer (3273)
Cardiovascular disease (263)
Career advice (724)
Career pathing (12)
CAR-T (161)
CDC (17)
Cell therapy (428)
Cervical cancer (26)
Clinical research (47740)
Collaboration (843)
Company closure (2)
Compensation (292)
Complete response letters (40)
COVID-19 (1344)
CRISPR (31)
C-suite (367)
Cystic fibrosis (86)
Data (4884)
Decentralized trials (1)
Denatured (1)
Depression (97)
Diabetes (400)
Diagnostics (3517)
Digital health (19)
Diversity (1)
Diversity, equity & inclusion (17)
Drug discovery (125)
Drug pricing (100)
Drug shortages (24)
Duchenne muscular dystrophy (151)
Earnings (45579)
Editorial (28)
Employer branding (5)
Employer resources (50)
Events (44272)
Executive appointments (444)
FDA (11094)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (19)
Funding (598)
Gene editing (85)
Generative AI (17)
Gene therapy (289)
GLP-1 (891)
Government (1747)
Grass and pollen (3)
Guidances (347)
Healthcare (8542)
HIV (33)
Huntington's disease (25)
IgA nephropathy (54)
Immunology and inflammation (148)
Immuno-oncology (31)
Indications (81)
Infectious disease (1470)
Inflammatory bowel disease (105)
Inflation Reduction Act (6)
Influenza (60)
Intellectual property (183)
Interviews (175)
IPO (11552)
IRA (23)
Job creations (860)
Job search strategy (583)
JPM (27)
Kidney cancer (13)
Labor market (10)
Layoffs (153)
Leadership (11)
Legal (3249)
Liver cancer (63)
Longevity (10)
Lung cancer (466)
Lymphoma (294)
Machine learning (20)
Management (23)
Manufacturing (373)
MASH (135)
Medical device (6736)
Medtech (6764)
Mergers & acquisitions (9610)
Metabolic disorders (1180)
Multiple sclerosis (125)
NASH (13)
Neurodegenerative disease (167)
Neuropsychiatric disorders (54)
Neuroscience (1832)
NextGen: Class of 2026 (2283)
Non-profit (1219)
Now hiring (3)
Obesity (657)
Opinion (135)
Ovarian cancer (122)
Pain (130)
Pancreatic cancer (176)
Parkinson's disease (180)
Partnered (15)
Patents (360)
Patient recruitment (319)
Peanut (29)
People (21829)
Pharmaceutical (9)
Pharmacy benefit managers (8)
Phase 1 (14303)
Phase 2 (21317)
Phase 3 (16148)
Pipeline (3907)
Policy (126)
Postmarket research (1393)
Preclinical (5265)
Press Release (9)
Prostate cancer (151)
Psychedelics (21)
Radiopharmaceuticals (149)
Rare diseases (464)
Real estate (1433)
Recruiting (18)
Regulatory (14035)
Reports (16)
Research institute (945)
Resumes & cover letters (143)
Rett syndrome (23)
RNA editing (7)
RSV (37)
Schizophrenia (111)
Series A (83)
Series B (63)
Service/supplier (2)
Sickle cell disease (50)
Special edition (7)
Spinal muscular atrophy (96)
Sponsored (18)
Startups (965)
Stomach cancer (7)
Supply chain (58)
Tariffs (31)
The Weekly (58)
Vaccines (509)
Venture capital (35)
Weight loss (431)
Women's health (45)
Worklife (5)
Date
Today (6)
Last 7 days (338)
Last 30 days (1360)
Last 365 days (18884)
2026 (1720)
2025 (19016)
2024 (21620)
2023 (24389)
2022 (29059)
2021 (31256)
2020 (28463)
2019 (20469)
2018 (15480)
2017 (16862)
2016 (14152)
2015 (17571)
2014 (12053)
2013 (8732)
2012 (9373)
2011 (10174)
2010 (9326)
Location
Africa (290)
Alabama (57)
Alaska (4)
Arizona (91)
Arkansas (6)
Asia (21177)
Australia (3334)
California (6778)
Canada (2276)
China (748)
Colorado (280)
Connecticut (323)
Delaware (224)
Europe (42813)
Florida (1148)
Georgia (175)
Hawaii (1)
Idaho (17)
Illinois (437)
India (38)
Indiana (379)
Iowa (13)
Japan (286)
Kansas (76)
Kentucky (10)
Louisiana (14)
Maine (54)
Maryland (854)
Massachusetts (4464)
Michigan (198)
Minnesota (319)
Mississippi (1)
Missouri (63)
Montana (19)
Nebraska (6)
Nevada (85)
New Hampshire (57)
New Jersey (2152)
New Mexico (4)
New York (2037)
North Carolina (730)
North Dakota (3)
Northern California (3329)
Ohio (140)
Oklahoma (8)
Oregon (9)
Pennsylvania (1456)
Puerto Rico (20)
Rhode Island (13)
South America (510)
South Carolina (51)
Southern California (2707)
Tennessee (100)
Texas (1162)
United States (24259)
Utah (185)
Virginia (170)
Washington D.C. (40)
Washington State (585)
West Virginia (2)
Wisconsin (33)
Wyoming (1)
332,049 Results for "airstrip ob".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
January 7, 2026
·
18 min read
Press Releases
Ob Hospitalist Group Appoints Dr. Lisa Bukovac as Chief Clinical Officer
November 19, 2025
·
3 min read
Depression
Biogen’s Zurzuvae Strategy Shifts as OB/GYNs Rise to the Front Lines
Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in postpartum depression.
May 28, 2025
·
5 min read
·
Annalee Armstrong
FDA Clears Clarius OB AI for Handheld Ultrasound: A Leap Forward in Prenatal Care
Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, has obtained FDA clearance for the Clarius OB AI fetal biometric measurement tool, improving access to obstetrical (OB) prenatal monitoring and care in resource-limited areas.
June 25, 2024
·
3 min read
Business
Nantworks AirStrip® and GE HealthCare Announce Agreement to Commercialize Integrated Patient Monitoring and Cardiac Data Visualization for Healthcare Systems
GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and AirStrip, a vendor-agnostic clinical surveillance technology company and a member of the Nantworks group of AI driven companies, announced today a joint commercialization agreement.
December 4, 2023
·
5 min read
Press Releases
Laborie Acquires the JADA® System for Rapid Postpartum Hemorrhage Control, Expanding Obstetrics Portfolio
January 29, 2026
·
4 min read
Press Releases
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
November 11, 2024
·
18 min read
Obesity
Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026
Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.
February 6, 2026
·
4 min read
·
Mark Zipkin
Earnings
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
February 4, 2026
·
2 min read
·
Tristan Manalac
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
1 of 33,205
Next
